Stifel Financial Corp Purchases 8,142 Shares of DexCom, Inc. (NASDAQ:DXCM)

Stifel Financial Corp grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 101,013 shares of the medical device company's stock after acquiring an additional 8,142 shares during the quarter. Stifel Financial Corp's holdings in DexCom were worth $7,856,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in DexCom during the 3rd quarter valued at $1,020,000. Pine Valley Investments Ltd Liability Co raised its stake in shares of DexCom by 59.2% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company's stock valued at $381,000 after buying an additional 2,111 shares during the last quarter. World Investment Advisors LLC acquired a new position in shares of DexCom in the 3rd quarter valued at $2,351,000. Wilmington Savings Fund Society FSB acquired a new position in DexCom in the 3rd quarter worth about $381,000. Finally, Tidal Investments LLC grew its position in shares of DexCom by 68.0% in the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company's stock valued at $2,463,000 after purchasing an additional 14,872 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 1.6 %

Shares of DXCM traded down $1.12 on Thursday, reaching $70.26. The company's stock had a trading volume of 6,865,096 shares, compared to its average volume of 4,222,913. The stock has a market capitalization of $27.55 billion, a PE ratio of 49.13, a PEG ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $132.26. The firm has a fifty day moving average of $72.01 and a 200-day moving average of $76.67.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business's revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 earnings per share. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on DXCM shares. Mizuho started coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target for the company. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and lifted their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $99.00.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,926 shares of company stock worth $4,734,384. Company insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.